Share This Info:  

For Sale: Pharmaceutical Company - Targeting Drug Delivery - Irvine, Orange County


Current Status: Active     Posting #: 245979     Last Refreshed: 5/18/20    
Contact: Rick Carlson At 833-776-6682 X769  -  Also Email This Contact Below
Price:  $20,000,000     Down:  Call     Adjusted Net:  Call     Revenue:  Call    
Business Address:  None Given     City:  Irvine     Zip:  92614    
Attributes:  Financial Assistance, Training & Support, Owner Financing     Cooperation With Brokers?  Yes

  Email Rick Carlson Below About This Posting
Your Name:
      Your Email:
      Your Phone:
Your Questions And Message To Rick Carlson: 

No Spam
For Best Results & Response, Email & Phone This Contact: Rick Carlson at 833-776-6682 X769.

  Description About This Posting: Pharmaceutical Company - Targeting Drug Delivery
Patented Universal Tumor-Targeting Drug Delivery Platform Co. This pharmaceutical company has developed and patented a universal tumor-targeting drug-delivery platform that can improve the safety and efficacy of many existing chemo treatments, with the ability to target numerous different types of cancer. The technology encapsulates existing FDA-approved drugs inside lipid nanoparticles (liposomes or emulsions) coated with patented human-sourced antinuclear antibodies (ANA). The lipid nanoparticle provides long-term storage stability of the drug and controlled release of the drug over time at body-temperature, and is expected to improve the safety and efficacy profile of the drug, including passive accumulation at the tumor while not harming normal tissues. The Company's ANA, sourced from lupus patients, binds to nuclear material present in abundance in areas of necrosis (dead / ruptured cells) present in and around all solid tumors, thus anchoring the drug-filled nanoparticles at the tumor where the nanoparticle is designed to slowly release the drug directly on the tumor for more effect. As the Company's ANA is not tumor-marker specific, but rather targets necrosis present in solid tumors, the technology is designed to "universally" target many different types of cancer including breast cancer, lung, ovarian, colon, prostate, etc., as well as rare childhood cancers.

The Company completed a successful proof-of-concept study at Children's Hospital using Ewing's Sarcoma transplanted in immunodeficient mice. Treatment with the Company's forumlation significantly inhibited tumor growth and extended survival times compared to control mice receiving no treatment or treatment with plain liposomal doxorubicin.

The Company has been granted Orphan Drug Designation by the FDA on 2 of the lead drug formulations, providing FDA fee waivers, priority review, and 7-years exclusivity upon market approval. The orphan pathway also enables the potential for New Drug Approval after successful completion of Phase 2 studies, with Phase III data collected while in the market, thus significantly lowering the time and cost to market approval. This same drug inside the Company's tumor targeting delivery system will likely have potential to treat other pediatric cancers, and/or cancers in larger adult populations.

As the Company's platform and ANA has the potential to improve the safety and efficacy of many existing FDA approved drugs or even compounds in development, the Company anticipates the potential for multiple licensing agreements with multiple pharmaceutical companies seeking to improve their existing portfolio and extend patient life as they advance into clinical stage. And as it may be possible to file for New Drug Approval following successful Phase II studies, the Company anticipates licensing potential at early clinical stage. Multiple exit opportunities exist with high impact & high ROI.

The Company is seeking a supportive capital partner to maintain momentum up to $20M. Funding will be used to advance the lead drug through formal Investigational New Drug enabling studies towards New Drug Approval; estimating $3-5 Million now to advance into clinical studies. Preclinical / animal studies estimate ($3 - 5 Million and 12-18 months); follwed by potential combined Phase I-II clinical study in a rare cancer (approximately 2-3 years and $10M) to potential New Drug Approval, plus additional capital to advance additional drugs in the pipeline simultaneously, thus adding tremendous value to the Company's valuation. Valuations of pharma companies often exceed $100 Million valuation at Phase I (approx. 18 months), and New Drug Approval can exceed valuations above $1 Billion. The Company has numerous, improved high-impact cancer drugs advancing with proper support.

NDA is required for comprehensive Confidential Information Memorandum crafted by ProNova Partners.

Detailed Information

Competition: Trying to improve existing therapies and develop novel approaches to hard to treat cancers.

Growth & Expansion: Huge market potential.

Financing: If the price and deal structure is right.

Support & Training: Transition team included.

Reason for Selling: Seeking supportive capital partners to take to the next level(s).

To get more information about this Pharmaceutical Company - Targeting Drug Delivery business for sale in Irvine, Orange County please phone Rick Carlson (Agent - BRE License #:01820673) at 833-776-6682 X769 - if you get voicemail please leave a detailed message - make sure you mention you saw this posting/ad #245979 on BizBen.com. In addition to phoning Rick Carlson, make sure you email Rick Carlson above to get more info about this Pharmaceutical Company - Targeting Drug Delivery, to ask any questions or request an appointment to see this business for sale. Thank you.

  Related Links And Information Regarding This Posting
Notes
My Posting Notes


  Helpful Resources To Assist In Selling And Buying California Businesses


  Related Articles, Events, Blog Posts, Discussions, Videos, Interviews

Know These 8 Factors That Matter
Pricing A Small Busienss
Jim Saxton Liquor License Broker Consultant
Why Restaurant Buyers Fail
Coronavirus Discussion Buying Selling Businesses
Buying a Commercial Cleaning Franchise


Close
Facebook
Twitter
Linkedin
Vlogs and Podcasts
Business For Sale California Stats
Advertise On BizBen
BizBen Blogs And Articles
New Postings Reports On BizBen Sign Up
BizBen ProBuy Program
Instant Email Alerts On BizBen

BizBen - Where California Deals Get Done! 888-212-4747
7172 Regional Street #364 · Dublin, CA. 94568
BizBen · Copyright © 1994 - 2020, All Rights Reserved



Clost Login


Please confirm your registration by clicking the link we've sent to .

If you can't see it, please check your junk mail folder.

If you have any problems registering, or need assistance with your new BizBen User Account please phone BizBen Customer Support at 888-212-4747.



First Name:*
Last Name:*
Email Address:*
Confirm Email:*
Create Password:*
Confirm Password:*
Phone:
(   
 


You Are A:
Individual
 
Intermediary
 

Email Address:
Password:
 

500 New & Refreshed Detailed Postings Daily
Over 2500 Resources Available On BizBen
Since 1994. Where California Deals Get Done!
FREE Online Webinar This Week: For Buyers - How To Buy & Value Laundroma...
Read More News
When Buying A Liquor Store - Is Location Important? Many Items Factor In...
Read More News